EsophagectomyPhase 4NCT06271707
Stellate Ganglion Block
A Phase 4 study testing 0.5% bupivacaine and Saline in people with Esophagectomy and Pneumonectomy, run by University of Minnesota at 1 site in United States.
Trial summary
The purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Esophagectomy, Pneumonectomy, Lobectomy
- What is being tested?
- 0.5% bupivacaine and Saline
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 1 siteUnited States
- Study dates
- 19 May 2025to 30 Dec 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients undergoing esophagectomy, pneumonectomy, or lobectomy aged 18-85.
Who cannot join
- Patients who have an exclusion to regional anesthesia.
- Patients who have exclusion to stellate blockade.
- Patients who are pregnant assessed via self-report or pregnancy test if they have taken one
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Candace Nelson contact
United States1 site, 1 recruiting
- Recruiting
University of Minnesota
Minneapolis, Minnesota, 55455
Candace Nelson, 612-626-2465, nelso377@umn.edu
About this study
Official title: Left Sided Stellate Ganglion Blocks Impact on the Rate of Post-operative Atrial Fibrillation in Patients Undergoing Thoracic Surgery: A Pilot Study
The purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.
- Conditions
- Esophagectomy, Pneumonectomy, Lobectomy
- Being tested
- 0.5% bupivacaine, Saline
- Keywords
- Esophagectomy, Pneumonectomy, Lobectomy, Stellate Ganglion Block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
0.5% bupivacaineDrug
an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine
SalineOther
an ultrasound guided left stellate ganglion block with 5 mL of saline
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | ultrasound with bupivacaine Receives: Drug: 0.5% bupivacaine |
| Group 2 | Sham comparator | Ultrasound with saline Receives: Other: Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
an ultrasound guided left stellate ganglion block with 5 mL of saline.
Incidence of Atrial fibrillation in the first 168 hours after surgery.
Measured: 168 hours after surgery
Atrial fibrillation; Other arrhythmias; Adverse events.
Atrial fibrillation in first 24, 48, 72, 96, 120, and 144 hours; Other arrhythmias in first 24, 48, 72, 96, 120, 144 and 168 hours; Adverse events.
Measured: 168 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2024
- Study start19 May 2025
- Primary completion30 Dec 2028 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EsophagectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jacob Hutchins, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06271707
- Sponsor's protocol ID
- ANES-2024-32720
- Status last verified
- Aug 2026
- First submitted
- 14 Feb 2024
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Left Sided Stellate Ganglion Blocks Impact on the Rate of Post-operative Atrial Fibrillation in Patients Undergoing Thoracic Surgery: A Pilot Study
- ClinicalTrials.gov ID
- NCT06271707
- Acronym / sponsor ID
- ANES-2024-32720
- Conditions
- Esophagectomy, Pneumonectomy, Lobectomy
- Keywords
- Esophagectomy, Pneumonectomy, Lobectomy, Stellate Ganglion Block
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- 19 May 2025 (actual)
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 22 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Drug: 0.5% bupivacaineultrasound with bupivacaine |
| Group 2 | Sham comparator | Other: SalineUltrasound with saline |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients undergoing esophagectomy, pneumonectomy, or lobectomy aged 18-85.
Key exclusion criteria (3 listed)
- Patients who have an exclusion to regional anesthesia.
- Patients who have exclusion to stellate blockade.
- Patients who are pregnant assessed via self-report or pregnancy test if they have taken one
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 0.5% bupivacainean ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine | Drug | Group 1 |
| Salinean ultrasound guided left stellate ganglion block with 5 mL of saline | Other | Group 2 |
Primary outcome
an ultrasound guided left stellate ganglion block with 5 mL of saline.
Time frame: 168 hours after surgery
Incidence of Atrial fibrillation in the first 168 hours after surgery.
Atrial fibrillation; Other arrhythmias; Adverse events.
Time frame: 168 hours after surgery
Atrial fibrillation in first 24, 48, 72, 96, 120, and 144 hours; Other arrhythmias in first 24, 48, 72, 96, 120, 144 and 168 hours; Adverse events.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
Related trials for Esophagectomy
Recruiting
Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.
Abdomen Cancer, Pancreas Adenocarcinoma (MSI-H)
RecruitingPhase 3
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
Esophageal Cancer
RecruitingPhase 2
OBSiDiAN in a Stapled Circular Esophagogastric Anastomosis After Ivor Lewis Esophagectomy
Anastomotic Leak Esophagus
Active, not recruitingObservational study
Endoluminal Vacuum Therapy to Prevent Anastomotic Leakage After Esophagectomy Due to Esophageal Cancer
Esophageal Cancer, Esophagus Cancer
Recruiting
PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies
Esophageal Cancer, Esophagectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Candace Nelson contact
Jacob Hutchins principal investigator
University of Minnesota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing 0.5% bupivacaine and Saline in people with Esophagectomy and Pneumonectomy, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Candace Nelson (nelso377@umn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
an ultrasound guided left stellate ganglion block with 5 mL of saline. (time frame: 168 hours after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.